Mutant CALR peptide vaccine
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-28 — Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm: Early-phase trial evaluating safety and tolerability of a mutant CALR peptide vaccine in patients with CALR-mutated MPN (first-in-class neoantigen vaccine approach; trial-early evidence, efficacy endpoints not yet reported). (novelty: 4)
Open questions
Related
Contributing findings
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
28-sep-2026
novelty 4
per-area 4
introduces
Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms.
18-aug-2026
novelty 2
per-area 2
introduces